tradingkey.logo

Qiagen NV

QGEN
查看詳細走勢圖
39.710USD
-0.920-2.26%
收盤 03/26, 16:00美東報價延遲15分鐘
7.93B總市值
20.27本益比TTM

Qiagen NV

39.710
-0.920-2.26%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.26%

5天

-2.31%

1月

-19.09%

6月

-9.54%

今年開始到現在

-11.84%

1年

+0.33%

查看詳細走勢圖

TradingKey Qiagen NV股票評分

單位: USD 更新時間: 2026-03-26

操作建議

Qiagen NV當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名22/391位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為54.27。中期看,股價處於下降通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Qiagen NV評分

相關信息

行業排名
22 / 391
全市場排名
101 / 4546
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Qiagen NV亮點

亮點風險
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入2.09B美元
估值低估
公司最新PE估值20.27,處於3年歷史低位
機構減倉
最新機構持股154.25M股,環比減少22.53%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉5.10K股

分析師目標

基於 18 分析師
持有
評級
54.265
目標均價
+36.41%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Qiagen NV新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Qiagen NV簡介

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
公司代碼QGEN
公司Qiagen NV
CEOBernard (Thierry)
網址https://www.qiagen.com/
KeyAI